JEMPERLI
PeakBLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
JEMPERLI by GSK is pd-1 ligands, pd-l1 and pd-l2, to the pd-1 receptor found on t cells inhibits t-cell proliferation and cytokine production. Approved for recurrent endometrial cancer (ec), advanced ec, determined by an fda-approved test and 5 more indications. First approved in 2021.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JEMPERLI (dostarlimab-gxly) is a humanized monoclonal antibody that blocks PD-1 receptor signaling to unleash anti-tumor immune responses. It is indicated for recurrent or advanced endometrial cancer with mismatch repair deficiency following prior platinum-based chemotherapy, and for advanced solid tumors meeting similar criteria. The drug restores T-cell proliferation and cytokine production by preventing PD-L1/PD-L2 interaction with PD-1.
$0.002BPart D
PeakPeak lifecycle stage with 50 linked jobs indicates an established commercial presence and active team expansion across multiple functions.
Mechanism of Action
PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.…
Indications (7)
Worked on JEMPERLI at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.